Friday, January 27, 2023

ARCH, General Catalyst launch clinical trial tech company Paradigm

https://ift.tt/tuPUAYf

Paradigm, a clinical trial technology company, has launched out of stealth with $203 million in Series A funding.

Paradigm will use the money to build a clinical research platform for provider and biopharmaceutical customers. The company has also acquired Deep Lens, a clinical trial patient recruitment company focused on oncology, for an undisclosed price.

Paradigm was conceived by venture capital firm ARCH Venture Partners and co-created by ARCH and General Catalyst, another venture capital firm. Along with ARCH and General Catalyst, investors in this stealth round include F-Prime Capital, GV, LUX Capital and Mubadala Capital, which is the state-owned investment firm for United Arab Emirates.

ARCH tapped clinical research industry veteran Kent Thoelke to Paradigm. Thoelke was chief scientific officer at PRA Health Sciences, which clinical research organization ICON acquired in 2021.

Along with Thoelke, Paradigm’s executive team includes a number of pharmaceutical digital health veterans. Milind Kamkolkar, the former chief data officer at Sanofi, is chief operating officer and Jonathan Hirsch, founder of real-world evidence company Syapse, is chief strategy and growth officer.

Clinical trials have become a popular target for disruption both by technology and retail players. There were 17 deals for digital health companies developing clinical trial technology, collectively valued at nearly $300 million, last year, according to Digital Health Business & Technology’s database. This potential has drawn interest from drugmakers such as GSK, the British pharmaceutical giant, which signed a four-year deal in September with Medable, a clinical trial software unicorn.

Retailers such as Walgreens Boots Alliance, CVS Health and The Kroger Co. have also entered the fray. Walgreens launched a clinical trial business in June to build a decentralized platform and offer in-person locations for recruiting and conducting clinical trials. CVS Health started a clinical trial division in 2021 and teamed with Medable for a virtual component last year. On Wednesday, Kroger announced its own clinical trial initiative in partnership with Persephone Biosciences.

This story first appeared in Digital Health Business & Technology.


Source link

source https://financetin.com/arch-general-catalyst-launch-clinical-trial-tech-company-paradigm/financetin.com

Related Posts:

  • Hundreds Sickened by Parasite in Bagged Salad The salads were made by Fresh Express at a plant in Illinois and may be contaminated with cyclospora. from WebMD Healthhttps://img.webmd.com/dtmcms/live/webmd/consumer_assets/site_images/article_thumbnails/news/2012/05_201… Read More
  • Lab-Created Virus Can Help COVID-19 Research Researchers said the hybrid virus could help scientists evaluate a range of antibody-based preventives and treatments for COVID-19. from WebMD Healthhttps://img.webmd.com/dtmcms/live/webmd/consumer_assets/site_images/artic… Read More
  • In Rush to Publish, Some COVID Studies Not Reliable Only 75 out of 664 clinical trials for COVID-19 -- about 11% -- have all the hallmarks of a scientific study that could be expected to produce solid results, according to the study published online July 27 in JAMA Internal M… Read More
  • Could the Flu Shot Lower Your Risk for Alzheimer's? Two new studies being presented Monday at this summer's virtual Alzheimer's Association International Conference found a lower incidence of Alzheimer's in people who got flu and pneumonia vaccines. from WebMD Healthhttps:/… Read More
  • How to Counter the Anti-Mask Backlash? Empathy As coronavirus cases in the United States soar, face mask mandates have been issued by a growing number of cities, states and national retailers. The mandates make sense, health experts say. from WebMD Healthhttps://img.we… Read More

0 comments:

Post a Comment